ClinicalTrials.gg
CompletedNCT05614895Updated Jan 22, 2024

A Study to Investigate the Pharmacokinetics of RO7223280 in Critically Ill Participants With Bacterial Infections

A Phase 1 interventional study of RO7223280 and RO7223280 in Bacterial Infections, sponsored by Hoffmann-La Roche. Completed at 16 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-01-22.

Sponsored by Hoffmann-La Roche · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jan 2024, 2 years 10 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 181 studies in Bacterial Infections with a site in United States — 12 open to participants now, 15 under way, 2 of them phase 3. Bacterial Infections · United States.

Enrollment
89th of 151
48 · median 62
Started
2022
with 5 others
Phase 1
66 of 181
2 open now
Registered
161st of 181
by date

Among the 181 studies in Bacterial Infections with a site in United States, this one is the 89th largest by enrollment of the 151 interventional ones that give a count, is one of 6 that started in 2022, is one of 66 in phase 1, and was the 161st registered.

Bacterial Infections

585 studies on the registry are indexed under Bacterial Infections; 84 are open to participants now.

Browse Bacterial Infections studies →

Open to participants now

12 of the 181 studies in Bacterial Infections with a site in United States are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 57 Bacterial Infections studies recruiting now, 38 (67%) set no upper age limit and 14 (25%) stop at 75 or younger; 19 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 181 studies in Bacterial Infections with a site in United States, or all of them as a file.
02

Study summary

The main aim of the study is to investigate the plasma pharmacokinetics (PK) and safety of intravenous (IV) administration of a single dose of 400 milligrams (mg) or 600 mg RO7223280 in critically ill participants with bacterial infections.

03

Conditions studied

  • Bacterial Infections

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Illness requiring treatment in an intensive care unit (ICU) at the time of enrolment
  • Ongoing clinical syndrome meeting at least one of the following criteria:

    1. HABP: bacterial pneumonia diagnosed after more than 48 hours of hospitalization or within 7 days after a hospital discharge
    2. Ventilator-associated bacterial pneumonia (VABP): bacterial pneumonia diagnosed after more than 48 hours of mechanical ventilation or within 72 hours after weaning
    3. Bacteremia confirmed by the presence of a bacterial pathogen in a blood culture drawn within 7 days prior to dosing and with the defined focus of infection.
    4. For Cohort 4 only: mechanically ventilated participants who have a BAL procedure planned as part of routine practice for a day that can function as Day 1.

Exclusion criteria

Exclusion Criteria:

  • Ongoing documented catheter-related bacteraemia as the sole ongoing infection
  • Major surgery within 48 hours prior to dosing or major surgery expected within 48 hours after the start of the infusion
  • Known chronic severe hepatic impairment ( class C). Note: acute severe hepatic impairment is not exclusionary
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    Cohort 1

    Bacteremia participants without pneumonia and who are not mechanically ventilated at screening will be enrolled in this cohort. Participants will receive RO7223280 on Day 1.

    Drug: RO7223280

  • Experimental
    Cohort 2

    Participants with hospital-acquired bacterial pneumonia (HABP) and who are not mechanically ventilated at screening will be enrolled in this cohort. Participants will receive RO7223280 on Day 1.

    Drug: RO7223280

  • Experimental
    Cohort 3

    Participants with mechanical ventilation at screening will be enrolled in this cohort. Participants will receive RO7223280 on Day 1.

    Drug: RO7223280

  • Experimental
    Cohort 4

    Participants with mechanical ventilation who have a bronchoalveolar lavage (BAL) planned as a part of routine practice will be enrolled in this cohort. Participants will receive RO7223280 on Day 1.

    Drug: RO7223280

Interventions

  • DrugRO7223280

    Participants will receive RO7223280, 600 mg, IV infusion for 1 hour on Day 1.

  • DrugRO7223280

    Participants will receive RO7223280, 400 mg, IV infusion for 1 hour on Day 1.

06

What researchers measure

Primary outcomes

  1. Plasma Concentrations of RO7223280

    Time frame: Cohort 1-3: From Day 1 up to Day 3; Cohort 4: From Day 1 up to Day 5

Secondary outcomes

  1. Percentage of Participants With Adverse Events (AEs)

    Time frame: Cohort 1-3: From Day 1 up to Day 4; Cohort 4: From Day 1 up to Day 5

  2. Percentage of Participants With Serious Adverse Events (SAEs)

    Time frame: Cohort 1-3: From Day 1 up to Day 4; Cohort 4: From Day 1 up to Day 5

  3. Percentage of Participants Who Died Due to Any Cause

    Time frame: Cohort 1-3: From Day 1 up to Day 4; Cohort 4: From Day 1 up to Day 5

07

Study locations

16 sites
  • Infectious Disease Associates
    Sarasota, Florida 34239, United States
  • University of Louisville Physicians
    Louisville, Kentucky 40202, United States
  • Beaumont Hospital; Royal Oak Pharmacy
    Royal Oak, Michigan 48073, United States
  • East Carolina University (ECU) Physicians - Infectious Disease Clinic - Greenville
    Greenville, North Carolina 27858-4353, United States
  • Oregon Health & Science University
    Portland, Oregon 97239, United States
  • Centre Hospitalier Régional Universitaire de Lille
    Lille, 59037, France
  • CHU de Limoges - Hôpital Dupuytren
    Limoges, 87042, France
  • Groupe Hospitalier Bichat Claude Bernard
    Paris, 75018, France
  • Hôpital Saint-Louis
    Paris, 75475, France
  • Hôpitaux Universitaires de strasbourg - hôpital civil
    Strasbourg, 67091, France
  • Hadassah Ein Karem Hospital
    Jerusalem, 9112001, Israel
  • The Chaim Sheba Medical Center; Multiple Sclerosis Center
    Ramat-Gan, 5262100, Israel
  • Tel-Aviv Sourasky Medical Center
    Tel Aviv, 6423906, Israel
  • Hallym University Kangnam Sacred Heart Hospital
    Seoul, 07441, Korea, Republic of
  • Asan Medical Center.
    Seoul, 5505, Korea, Republic of
  • ARENSIA Phase 1 Unit- Spitalul Clinic Republican Location
    Chisinau, MD-2025, Moldova, Republic of
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/innovation/process/clinical -trials/data-sharing/).

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2022 to primary completion in Jan 2024, 13 months.

Of 52 industry-sponsored phase 1 interventional studies under Bacterial Infections, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 13. This study's 13 months is above that.

Counting every sponsor, half of 67 studies reached it within 9 months; a quarter within 4 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2022
First posted
Nov 14, 2022
StartActual
Dec 3, 2022
Primary completionActual
Jan 13, 2024
CompletionActual
Jan 13, 2024
Last update
Jan 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05614895
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Nov 14, 2022
Start date
Dec 3, 2022
Primary completion
Jan 13, 2024
Completion
Jan 13, 2024
Last update
Jan 22, 2024

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion